Thrombocytopenia due to treatment of breast cancer
Conditions
Interventions
Trial Group:Treatment stage: Use Herombopag for treatment. Herombopag is started once a day after PLT200 * 10 ^ 9/L, then suspend administration, whichever occurs first.
Sponsors
Liaoning Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients voluntarily join this study and sign an informed consent form; 2. Age >= 18 years old, both male and female are eligible; 3. Breast cancer patients diagnosed as HER-2 positive by pathological examination; 4. Accept ADC drug treatment; 5. PLT3 months, with clear consciousness and no mental or cognitive impairment of the patient; 8. ECOG-PS score 0-1 points; 9. Able to comply with the research visit plan; 10. Female subjects with the ability to conceive must undergo a serum pregnancy test within 72 hours before the first dose, and the result must be negative, and they are willing to use effective contraceptive measures during the trial period and 6 months after the last dose. For male participants whose partners are women of childbearing age, surgical sterilization or agreement to use effective contraceptive measures during the trial period and 6 months after the last dose should be provided.
Exclusion criteria
Exclusion criteria: 1. Known to be allergic or intolerant to Herombopag Olamine Tablets or its excipients; 2. Women who are pregnant, breastfeeding, or have given birth but refuse to take contraceptive measures; 3. Unable to understand the nature of the research or without obtaining informed consent; 4. Have participated in any other drug clinical studies within 4 weeks prior to the first administration; 5. Known history of abuse or drug use of psychotropic substances; 6. There are other serious physical or mental illnesses or laboratory abnormalities that may increase the risk of participating in the study, or interfere with the study results, as well as patients who the researcher deems unsuitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of subjects with effective treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time for PLT to recover to>100 * 10 ^ 9/L;Proportion of patients receiving platelet boosting salvage therapy;ADC drug timely and sufficient dose treatment rate;The proportion and reasons for ADC drug interruption therapy/treatment delay/dose adjustment;The degree of thrombocytopenia after receiving different ADC drug treatments;The influence of baseline characteristics of different patients on treatment outcomes; | — |
Countries
China
Contacts
Public ContactZhang Xinfeng
Liaoning Cancer Hospital
Outcome results
None listed